Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Product ID

Click to order products ascending

Display 15 Products per page

Reyataz
Read More
The Reyataz franchise comprises the standalone azapeptide protease inhibitor (PI) Reyataz (atazanavir; Bristol-Myers Squibb) and the fixed-dose combination of Reyataz and Tybost.
June 28, 2019
Find out more
Rubraca
Read More
Rubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations or other homologous recombination gene alterations.
January 18, 2018
Find out more
Rytary
Read More
Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component.
June 21, 2018
Find out more
Atripla
Read More
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Azilect
Read More
Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline and without metabolizing into amphetamine derivatives.
June 21, 2018
Find out more
ChimeriVax-Dengue
Read More
ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs.
October 28, 2015
Find out more
Complera
Read More
Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson & Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Cubicin
Read More
Cubicin is a cyclic lipopeptide antibacterial that has a unique mechanism of action. It causes rapid depolarization of the bacterial cell membrane potential upon binding to the membrane.
September 10, 2014
Find out more
Entyvio
Read More
Entyvio (vedolizumab; Takeda) is a humanized monoclonal antibody approved for the treatment of Crohn’s disease and ulcerative colitis.
August 2, 2018
Find out more
Etrolizumab
Read More
Etrolizumab (Roche) is a humanized anti-beta 7 integrin subunit monoclonal antibody in Phase III development for the treatment of ulcerative colitis.
August 2, 2018
Find out more
Jevtana
Read More
Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.
January 18, 2018
Find out more
Kadcyla
Read More
Kadcyla (ado-trastuzumab emtansine; ImmunoGen/Roche/Chugai) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC), which contains the humanized anti-HER2 immunoglobulin G1 Herceptin.
March 9, 2015
Find out more
Ketek
Read More
Ketek (telithromycin; Sanofi) is an oral semisynthetic antibacterial agent of the ketolide class. The drug, which is the first ketolide to gain regulatory approval for the treatment of community-acquired pneumonia, is structurally related to the macrolide class of antibiotics.
June 19, 2015
Find out more
Midostaurin
Read More
Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML.
April 22, 2014
Find out more
TAK-003
Read More
TAK-003 (Takeda) is a needle-free, tetravalent live-attenuated vaccine currently in Phase II/III development in the US and dengue-endemic countries in Asia and Latin America, including Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Peru, the Philippines, Sri Lanka, Thailand, and Vietnam.
January 4, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *